Targeted Exon Skipping in Transgenic hDMD Mice: A Model for Direct Preclinical Screening of Human-Specific Antisense Oligonucleotides-Reference-Cited by-同舟云学术

Targeted Exon Skipping in Transgenic hDMD Mice: A Model for Direct Preclinical Screening of Human-Specific Antisense Oligonucleotides

Published:2004-08 Issue:2 Volume:10 Page:232-240
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Bremmer-Bout Mattie,Aartsma-Rus Annemieke,de Meijer Emile J.,Kaman Wendy E.,Janson Anneke A.M.,Vossen Rolf H.A.M.,van Ommen Gert-Jan B.,den Dunnen Johan T.,van Deutekom Judith C.T.

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference34 articles.

1. Dystrophin: the protein product of the Duchenne muscular dystrophy locus;Hoffman;Cell,1987

2. Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy;Hoffman;N. Engl. J. Med,1988

3. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion;Koenig;Am. J. Hum. Genet,1989

4. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus;Monaco;Genomics,1988

5. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin;England;Nature,1990

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy;Nucleic Acid Therapeutics;2023-06-01

2. Investigating the Impact of Delivery Routes for Exon Skipping Therapies in the CNS of DMD Mouse Models;Cells;2023-03-15

3. Correction of DMD in human iPSC-derived cardiomyocytes by base-editing-induced exon skipping;Molecular Therapy - Methods & Clinical Development;2023-03

4. In Vivo Evaluation of Exon 51 Skipping in hDMD/Dmd-null Mice;Methods in Molecular Biology;2023

5. Lessons learned from developing an oligonucleotide drug for a rare disease;RNA Therapeutics;2022